Autopsy report · NCT03066154

Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer

“low inclusion of patients and availability of the IP”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 11 months before it stopped.
• 24 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

The Netherlands Cancer Institute

Sponsor type

University, hospital or other

Conditions

Prostatic Neoplasms

Interventions

oral docetaxel (ModraDoc/r); androgen deprivation therapy; high-dose intensity-modulated radiation therapy

Participants

24

Sites

1

Countries

Netherlands

Trials that died the same way

• Cetrotide Treatment Optimization
  “Due to limited rate of patient inclusion” (67% match in meaning)
• Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
  “Due to slow inclusion of patients” (65% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (63% match in meaning)
• The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
  “Lack of eligible patients” (62% match in meaning)
• Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
  “The rate of inclusion is too low to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives. The sponsor has decided to prematurely stop inclusions on January 13, 2022.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.